Subependymal giant cell astrocytoma physical examination: Difference between revisions
| Line 13: | Line 13: | ||
===Vital Signs=== | ===Vital Signs=== | ||
*Vital signs of patients with | *Vital signs of patients with subependymal giant cell astrocytoma are usually normal. | ||
===Skin=== | |||
*Skin examination of patients with subependymal giant cell astrocytoma is usually normal. | |||
Revision as of 00:16, 28 October 2019
|
Subependymal giant cell astrocytoma Microchapters |
|
Differentiating Subependymal Giant Cell Astrocytoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Subependymal giant cell astrocytoma physical examination On the Web |
|
American Roentgen Ray Society Images of Subependymal giant cell astrocytoma physical examination |
|
FDA on Subependymal giant cell astrocytoma physical examination |
|
CDC on Subependymal giant cell astrocytoma physical examination |
|
Subependymal giant cell astrocytoma physical examination in the news |
|
Blogs on Subependymal giant cell astrocytoma physical examination |
|
Risk calculators and risk factors for Subependymal giant cell astrocytoma physical examination |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]
Overview
Common physical examination findings of subependymal giant cell astrocytoma include papilledema, vision field defects, developmental delay, mental retardation, aphasia, sensory loss, and hemiparesis.[1][2]
Physical Examination
Common physical examination findings of subependymal giant cell astrocytoma include:[1][2][3][4]
Appearance
- Patients with subependymal giant cell astrocytoma usually appear normal.
Vital Signs
- Vital signs of patients with subependymal giant cell astrocytoma are usually normal.
Skin
- Skin examination of patients with subependymal giant cell astrocytoma is usually normal.
HEENT
- Ophthalmoscopic exam may be abnormal with findings of papilledema and visual field defects.
Neurological
References
- ↑ 1.0 1.1 Sasongko, Teguh Haryo; Ismail, Nur Farrah Dila; Nik Abdul Malik, Nik Mohamad Ariff; Zabidi-Hussin, Z. A. M. H. (2015). "Rapamycin and its analogues (rapalogs) for Tuberous Sclerosis Complex-associated tumors: a systematic review on non-randomized studies using meta-analysis". Orphanet Journal of Rare Diseases. 10 (1). doi:10.1186/s13023-015-0317-7. ISSN 1750-1172.
- ↑ 2.0 2.1 Ouyang, Taohui; Zhang, Na; Benjamin, Thomas; Wang, Long; Jiao, Jiantong; Zhao, Yiqing; Chen, Jian (2014). "Subependymal giant cell astrocytoma: current concepts, management, and future directions". Child's Nervous System. 30 (4): 561–570. doi:10.1007/s00381-014-2383-x. ISSN 0256-7040.
- ↑ Roth, Jonathan; Roach, E. Steve; Bartels, Ute; Jóźwiak, Sergiusz; Koenig, Mary Kay; Weiner, Howard L.; Franz, David N.; Wang, Henry Z. (2013). "Subependymal Giant Cell Astrocytoma: Diagnosis, Screening, and Treatment. Recommendations From the International Tuberous Sclerosis Complex Consensus Conference 2012". Pediatric Neurology. 49 (6): 439–444. doi:10.1016/j.pediatrneurol.2013.08.017. ISSN 0887-8994.
- ↑ Goh S, Butler W, Thiele EA (2004). "Subependymal giant cell tumors in tuberous sclerosis complex". Neurology. 63 (8): 1457–61. doi:10.1212/01.wnl.0000142039.14522.1a. PMID 15505165.